| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-2732SS | |||
| Azide and BSA Free | NBP2-80779 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-1828SS | |||
| Azide and BSA Free | NBP2-80880 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-06398SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | BC100-520SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NBP2-33122-100ug | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-87102-25ul | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-598SS | |||
| Azide and BSA Free | NBP2-80600 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NBP2-80671 | |||
| BSA Free | NB100-136SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-96140SS | |||
| Azide and BSA Free | NBP2-80599 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-353SS | |||
| Azide and BSA Free | NBP2-80606 | |||
![Western Blot: NKX3.1 Antibody (0361) [NB100-1828] - Analysis of NKX3.1 in HeLa cell lysate using anti-NKX3.1 antibody. WB image submitted by a verified customer review.](http://images.novusbio.com/fullsize/NKX3-1-Antibody-0361-Western-Blot-NB100-1828-img0006.jpg "Western Blot: NKX3.1 Antibody (0361) [NB100-1828] - Analysis of NKX3.1 in HeLa cell lysate using anti-NKX3.1 antibody. WB image submitted by a verified customer review.")
![Immunohistochemistry-Paraffin: NKX3.1 Antibody (0361) [NB100-1828] - Staining of human chondrosarcoma tissue with NKX3.1 monoclonal antibody. IHC-P image submitted by a verified customer review.](http://images.novusbio.com/fullsize/NKX3-1-Antibody-0361-Immunohistochemistry-Paraffin-NB100-1828-img0008.jpg)
![Western Blot: Nkx3.1 Antibody (0361) [NB100-1828] - Detection of NKX3.1 in mouse testis lysate using NB 100-1828. ECL detection 1 minute.](http://images.novusbio.com/fullsize/Nkx3-1-Antibody-0361-Western-Blot-NB100-1828-img0003.jpg)
![Immunohistochemistry-Paraffin: NKX3.1 Antibody (0361) [NB100-1828] - NKX3.1 was detected in immersion fixed paraffin-embedded sections of mouse testis using Mouse Anti-Mouse NKX3.1 (0361) Monoclonal Antibody (Catalog # NB100-1828) at 1:300 for 1 hour at room temperature followed by incubation with the Anti-Mouse IgG VisUCyte™ HRP Polymer Antibody (Catalog # VC001). Tissue was stained using DAB (brown) and counterstained with hematoxylin (blue). Specific staining was localized to the nuclei in sperm cells.](http://images.novusbio.com/fullsize/NKX3-1-Antibody-0361-Immunohistochemistry-Paraffin-NB100-1828-img0007.jpg)
![<b>Genetic Strategies Validation. </b>Western Blot: NKX3.1 Antibody (0361) [NB100-1828] - DWB analysis of NKX3.1 expression in the indicated cells transfected with Ri-Vector (V-Ri) or shRNAs (Ri#1/2) against NKX3.1. Image collected and cropped by CiteAb from the following publication (//www.ncbi.nlm.nih.gov/pmc/articles/PMC6895605/) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/NKX3-1-Antibody-0361-Knockdown-Validated-NB100-1828-img0009.jpg)
![Western Blot: NKX3.1 Antibody (0361) - BSA Free [NB100-1828] - SALL2 transcriptionally upregulates ESR1 in breast cancerARNA‐seq analysis of ESR1 mRNA levels in 9 paired pre‐tamoxifen‐treated primary breast cancer tissues & relapsed tamoxifen‐resistant breast cancer tissues.BqRT–PCR analysis of ESR1 expression in 9 paired pre‐tamoxifen‐treated primary breast cancer tissues & relapsed tamoxifen‐resistant breast cancer tissues. GAPDH was used as an internal control.C, DWB analysis of SALL2 (A) & NKX3‐1 (B) expression in the indicated cells transfected with Ri‐Vector (V‐Ri) or shRNAs (Ri#1/2) against SALL2 or NKX3‐1. alpha ‐Tubulin was used as the loading control.E, FqRT–PCR analysis of ESR1 expression in the indicated cells transfected with Ri‐Vector or shRNAs (Ri#1/2) against SALL2 or NKX3‐1.Data information: In (A), P‐values were determined by two‐tailed paired Student's t‐test. In (B), data are presented as mean ± SD, & P‐values were determined by two‐tailed unpaired Student's t‐test, n = 3. In (E & F), data are presented as mean ± SD, & P‐values were determined by one‐way ANOVA test, n = 3. *P < 0.05, **P < 0.01, ***P < 0.001, n.s., no significance. Exact P‐values are specified in Appendix Table S10.Source data are available online for this figure. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31657150), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-1828_mouse-monoclonal-nkx3-1-antibody-0361-310202415525249.jpg)
![Immunohistochemistry: Glutathione Peroxidase 3/GPX3 Antibody [NBP1-06398] - GPX3 expressions in adenocarcinoma (AC). EnVision immunohistochemistry, original magnification x200. GPX3 positive reaction was mainly localized in the cytoplasm. Negative GPX3 expression in poorly differentiated AC (c), and positive GPX3 expression in well-differentiated AC (d). Image collected and cropped by CiteAb from the following publication (//www.hindawi.com/journals/dm/2013/187043/), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Glutathione-Peroxidase-3-GPX3-Antibody-Immunohistochemistry-NBP1-06398-img0007.jpg "Immunohistochemistry: Glutathione Peroxidase 3/GPX3 Antibody [NBP1-06398] - GPX3 expressions in adenocarcinoma (AC). EnVision immunohistochemistry, original magnification x200. GPX3 positive reaction was mainly localized in the cytoplasm. Negative GPX3 expression in poorly differentiated AC (c), and positive GPX3 expression in well-differentiated AC (d). Image collected and cropped by CiteAb from the following publication (//www.hindawi.com/journals/dm/2013/187043/), licensed under a CC-BY license.")
![Immunohistochemistry: Glutathione Peroxidase 3/GPX3 Antibody [NBP1-06398] - GPX3 expressions in squamous carcinomas/adenosquamous carcinomas (SC/ASC). EnVision immunohistochemistry, original magnification x200. GPX3 positive reaction was mainly localized in the cytoplasm. Negative GPX3 expression in poorly differentiated SC/ASC (c). Positive GPX3 expression in well-differentiated SC/ASC (d). Image collected and cropped by CiteAb from the following publication (//www.hindawi.com/journals/dm/2013/187043/), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Glutathione-Peroxidase-3-GPX3-Antibody-Immunohistochemistry-NBP1-06398-img0006.jpg)
![Western Blot: Glutathione Peroxidase 3/GPX3 Antibody [NBP1-06398] - Analysis of GPX3 in human kidney lysate.](http://images.novusbio.com/fullsize/Glutathione-Peroxidase-3-GPX3-Antibody-Western-Blot-NBP1-06398-img0002.jpg)
![Immunohistochemistry-Paraffin: Glutathione Peroxidase 3/GPX3 Antibody [NBP1-06398] - IHC analysis of formalin fixed paraffin-embedded (FFPE) human kidney using 1:200 conc. of Glutathione Peroxidase 3 antibody on a Bond Rx autostainer (Leica Biosystems). The assay involved 20 minutes of heat induced antigen retrieval (HIER) using 10mM sodium citrate buffer (pH 6.0) and endogenous peroxidase quenching with peroxide block. The sections were incubated with primary antibody for 30 minutes and Bond Polymer Refine Detection (Leica Biosystems) with DAB was used for signal development followed by counterstaining with hematoxylin. Whole slide scanning and capturing of representative images was performed using Aperio AT2 (Leica Biosystems). Cytoplasmic staining of Glutathione Peroxidase 3 was observed. Staining was performed by Histowiz.](http://images.novusbio.com/fullsize/Glutathione-Peroxidase-3-GPX3-Antibody-Immunohistochemistry-Paraffin-NBP1-06398-img0005.jpg)
![Immunocytochemistry/Immunofluorescence: Glutathione Peroxidase 3/GPX3 Antibody [NBP1-06398] - The GPX3 antibody was tested in HeLa cells at a 1:250 dilution against Dylight 488 (Green). Alpha-tubulin and nuclei were counterstained against Dylight 550 (Red) and DAPI blue).](http://images.novusbio.com/fullsize/Glutathione-Peroxidase-3-GPX3-Antibody-Immunocytochemistry-Immunofluorescence-NBP1-06398-img0003.jpg)
![Immunohistochemistry: Glutathione Peroxidase 3/GPX3 Antibody [NBP1-06398] - ALDH1A3 & GPX3 expressions in squamous carcinomas/adenosquamous carcinomas (SC/ASC). EnVision immunohistochemistry, original magnification ×200. ALDH1A3 & GPX3 positive reaction was mainly localized in the cytoplasm. (a), positive ALDH1A3 expression in poorly differentiated SC/ASC. (b), negative ALDH1A3 expression in well-differentiated SC/ASC. (c), negative GPX3 expression in poorly differentiated SC/ASC. (d), positive GPX3 expression in well-differentiated SC/ASC. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/24167362), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-06398_rabbit-polyclonal-glutathione-peroxidase-3-gpx3-antibody-31020241517522.jpg)
![Immunohistochemistry: Glutathione Peroxidase 3/GPX3 Antibody [NBP1-06398] - ALDH1A3 & GPX3 expressions in adenocarcinoma (AC). EnVision immunohistochemistry, original magnification ×200. ALDH1A3 & GPX3 positive reaction was mainly localized in the cytoplasm. (a), positive ALDH1A3 expression in moderately differentiated AC. (b), negative ALDH1A3 expression in well-differentiated AC. (c), negative GPX3 expression in poorly differentiated AC. (d), positive GPX3 expression in well-differentiated AC. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/24167362), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-06398_rabbit-polyclonal-glutathione-peroxidase-3-gpx3-antibody-310202415291925.jpg)
![Western Blot: OS9 Antibody [BC100-520] - Initial characterization of the OS-9 protein. OS-9 expression in various human cell lines. Equal protein amounts of total cell lysates were used for SDS-PAGE and subsequent Western blotting. For each cell line, two independent samples are shown. Endogenous OS-9 was detected with a polyclonal antibody raised against a peptide corresponding to amino acids 600-667 of isoform 1 of OS-9. Image collected and cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0019151), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/OS9-Antibody-Western-Blot-BC100-520-img0004.jpg "Western Blot: OS9 Antibody [BC100-520] - Initial characterization of the OS-9 protein. OS-9 expression in various human cell lines. Equal protein amounts of total cell lysates were used for SDS-PAGE and subsequent Western blotting. For each cell line, two independent samples are shown. Endogenous OS-9 was detected with a polyclonal antibody raised against a peptide corresponding to amino acids 600-667 of isoform 1 of OS-9. Image collected and cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0019151), licensed under a CC-BY license.")
![Immunocytochemistry/Immunofluorescence: OS9 Antibody [BC100-520] - OS9 antibody was tested in HeLa cells with FITC (green). Nuclei and alpha-tubulin were counterstained with Dapi (blue) and Dylight 550 (red).](http://images.novusbio.com/fullsize/OS9-Antibody-Immunocytochemistry-Immunofluorescence-BC100-520-img0002.jpg)
![Western Blot: OS9 Antibody [BC100-520] - WB analysis of OS9 in 1. A431 cell lysate, 2. HepG2 cell lysate, 3. MCF7 cell lysate and 4. 3T3 cell lysate.](http://images.novusbio.com/fullsize/OS9-Antibody-Western-Blot-BC100-520-img0001.jpg)
![Simple Western: OS9 Antibody [BC100-520] - Simple Western lane view shows a specific band for OS9 in 0.5 mg/ml of HepG2 lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/OS9-Antibody-Simple-Western-BC100-520-img0003.jpg)
![Western Blot: OS9 Antibody [BC100-520] - Initial characterization of the OS-9 protein.(A) OS-9 expression in various human cell lines. Equal protein amounts of total cell lysates were used for SDS-PAGE & subsequent Western blotting. For each cell line, two independent samples are shown. Endogenous OS-9 was detected with a polyclonal antibody raised against a peptide corresponding to amino acids 600–667 of isoform 1 of OS-9. (B) Protein stability assay of endogenous OS-9. U2OS cells were treated with the translational inhibitor cycloheximide (100 µM). At indicated time points, whole cell lysates were analysed by immunoblotting. (C) Effect of hypoxia on OS-9 expression. For hypoxia, UT-7 cells were exposed to 1% O2 for 24 h prior to Western blot analysis. To determine any influence of HIF-1 alpha on OS-9 expression under normoxia, cells were incubated with the prolyl hydroxylase inhibitor DMOG (0.5 mM) for 24 h. (D) Protein interaction between OS-9 & PHD2 in vitro. For co-immunoprecipitation, U2OS cells were transiently co-transfected with the plasmids pOS-9-V5 & pPHD2-His, lysed in NP40 buffer, & subjected to immunoisolation with anti-V5 antibody recognizing OS-9 by its V5-tag. OS-9 & its associated proteins were separated by SDS-PAGE & analyzed by Western blot (lane 2). As controls, samples of untransfected (lane 1) cells or cells transfected with a single plasmid (lanes 3–4) were loaded. Representative Western blots are shown for each subfigure. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/21559462), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/bc100-520_rabbit-polyclonal-os9-antibody-310202415482216.jpg)
![Western Blot: OS9 Antibody [BC100-520] - Initial characterization of the OS-9 protein.(A) OS-9 expression in various human cell lines. Equal protein amounts of total cell lysates were used for SDS-PAGE & subsequent Western blotting. For each cell line, two independent samples are shown. Endogenous OS-9 was detected with a polyclonal antibody raised against a peptide corresponding to amino acids 600–667 of isoform 1 of OS-9. (B) Protein stability assay of endogenous OS-9. U2OS cells were treated with the translational inhibitor cycloheximide (100 µM). At indicated time points, whole cell lysates were analysed by immunoblotting. (C) Effect of hypoxia on OS-9 expression. For hypoxia, UT-7 cells were exposed to 1% O2 for 24 h prior to Western blot analysis. To determine any influence of HIF-1 alpha on OS-9 expression under normoxia, cells were incubated with the prolyl hydroxylase inhibitor DMOG (0.5 mM) for 24 h. (D) Protein interaction between OS-9 & PHD2 in vitro. For co-immunoprecipitation, U2OS cells were transiently co-transfected with the plasmids pOS-9-V5 & pPHD2-His, lysed in NP40 buffer, & subjected to immunoisolation with anti-V5 antibody recognizing OS-9 by its V5-tag. OS-9 & its associated proteins were separated by SDS-PAGE & analyzed by Western blot (lane 2). As controls, samples of untransfected (lane 1) cells or cells transfected with a single plasmid (lanes 3–4) were loaded. Representative Western blots are shown for each subfigure. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/21559462), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/bc100-520_rabbit-polyclonal-os9-antibody-310202415483621.jpg)
![Western Blot: OS9 Antibody [BC100-520] - Initial characterization of the OS-9 protein.(A) OS-9 expression in various human cell lines. Equal protein amounts of total cell lysates were used for SDS-PAGE & subsequent Western blotting. For each cell line, two independent samples are shown. Endogenous OS-9 was detected with a polyclonal antibody raised against a peptide corresponding to amino acids 600–667 of isoform 1 of OS-9. (B) Protein stability assay of endogenous OS-9. U2OS cells were treated with the translational inhibitor cycloheximide (100 µM). At indicated time points, whole cell lysates were analysed by immunoblotting. (C) Effect of hypoxia on OS-9 expression. For hypoxia, UT-7 cells were exposed to 1% O2 for 24 h prior to Western blot analysis. To determine any influence of HIF-1 alpha on OS-9 expression under normoxia, cells were incubated with the prolyl hydroxylase inhibitor DMOG (0.5 mM) for 24 h. (D) Protein interaction between OS-9 & PHD2 in vitro. For co-immunoprecipitation, U2OS cells were transiently co-transfected with the plasmids pOS-9-V5 & pPHD2-His, lysed in NP40 buffer, & subjected to immunoisolation with anti-V5 antibody recognizing OS-9 by its V5-tag. OS-9 & its associated proteins were separated by SDS-PAGE & analyzed by Western blot (lane 2). As controls, samples of untransfected (lane 1) cells or cells transfected with a single plasmid (lanes 3–4) were loaded. Representative Western blots are shown for each subfigure. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/21559462), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/bc100-520_rabbit-polyclonal-os9-antibody-310202415482293.jpg)
![Western Blot: OS9 Antibody [BC100-520] - Cellular localization of OS-9 & PHD2.(A) A lectin gel-shift assay was conducted to test for glycosylated proteins. Total cell lysates of U2OS cells were incubated in the presence or absence of the endoglycosidases EndoH & PNGaseF for 6 h at 37°C. Digest products were separated on a reducing 10% SDS-PAGE gel which contained concanavalin A co-polymerized in the top layer of the separating gel to retard mobility of glycosylated proteins [56]. Glycosylated OS-9 is indicated as ‘g’, deglycosylated OS-9 as ‘d’. (B) Detection of OS-9 & PHD2 in the nuclear fraction. HEK293 cells with & without transfection of the plasmid pcDNA3-OS-9 were separated into nuclear fraction (N) & postnuclear supernatant (PS), the latter containing cytoplasm & organelles. Western blot analysis included BiP, GAPDH & lamin A as typical marker proteins for the ER, the cytoplasm & the nucleus, respectively. (C) Detection of OS-9 & PHD2 in the cytoplasm. HEK293 cells were co-transfected with pcDNA3-OS-9 & pPHD2-V5. For hypoxia, cells were exposed to 3% O2 for 4 h. Cells were treated with 50 µg/ml digitonin & centrifuged to obtain a cytoplasmic (C) & an organelle fraction (O) & subjected to immunoblotting. (D) Isolation of cellular endomembranes. HEK293 cells were lysed mechanically by several passages through a 30½G needle. The postnuclear supernatant was processed further by ultra-centrifugation to separate the organelles (O) from the cytosol (C). High salt treatment (1 M KCl) of the organelle fraction produced a wash fraction (W) that contained dissociated peripheral membrane proteins. For immunoblot analysis of subcellular fractionations, cell aliquots were normalized for cell number prior to loading (B–D). Representative Western blots are shown for each subfigure. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/21559462), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/bc100-520_rabbit-polyclonal-os9-antibody-310202415483637.jpg)
![Western Blot: OS9 Antibody [BC100-520] - OS-9 shows no effect on regulation of HIF-1 alpha .Total cell lysates were used for SDS-PAGE & subsequent Western blotting. To generate nearly anoxic conditions, cells were exposed to an oxygen consuming chemical system or to 1% or 3% O2 for 4 h to generate hypoxia. (A) U2OS, HeLa & Hep3B cells were transiently transfected with the plasmid pOS-9-V5 48 h prior to the experiment. Lamin A & actin were used as loading controls. (B) U2OS cells were subjected to ER stress by incubation either with tunicamycin (1 µg/ml) or thapsigargin (0.5 µg/ml) for 20 h. To detect HIF-1 alpha under normoxia, cells were treated with DMOG (1 mM) for 4 h. A sample of DMSO-only treated cells was loaded to exclude unspecific side effects of the solvent. (C) U2OS cells were transduced with lentiviral construct pLKO.1-shRNA-OS-9 (shOS-9) mediating a stable knockdown of OS-9 expression. Control cells (c) were transduced with plasmid pLKO.1-puro. Representative Western blots are shown for each subfigure. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/21559462), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/bc100-520_rabbit-polyclonal-os9-antibody-310202415482250.jpg)
![Immunohistochemistry-Frozen: CD8 Antibody [NBP2-29475] - Mouse Ccdc88b expression in colon during DSS-induced colitis. Wild type (WT) mice were either not treated (NT) or given 3% DSS for 5 days followed by 3 days of water. Representative confocal microscopy images of tissue sections from colon of NT or DSS-treated mice at day 8, and stained for or Ccdc88b (red) and CD8 (green). Scale bars, 100 um. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29030607/) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/CD8-Antibody-Immunohistochemistry-Frozen-NBP2-29475-img0002.jpg "Immunohistochemistry-Frozen: CD8 Antibody [NBP2-29475] - Mouse Ccdc88b expression in colon during DSS-induced colitis. Wild type (WT) mice were either not treated (NT) or given 3% DSS for 5 days followed by 3 days of water. Representative confocal microscopy images of tissue sections from colon of NT or DSS-treated mice at day 8, and stained for or Ccdc88b (red) and CD8 (green). Scale bars, 100 um. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29030607/) licensed under a CC-BY license.")
![Immunohistochemistry-Frozen: CD8 Antibody [NBP2-29475] - Mouse Ccdc88b expression in colon during DSS-induced colitis. Wild type (WT) mice were either not treated (NT) or given 3% DSS for 5 days followed by 3 days of water. aCcdc88b mRNA expression in distal colons of NT (n = 3) or DSS-treated WT mice (n = 3 for each time point) at the indicated days. Data represent expression relative to hprt±SEM (n = 3). *P < 0.05, **P < 0.01 (two-tailed Student’s t-test) & are representative of one experiment. b Representative immunoblots for Ccdc88b protein detected in extracts from distal colons from NT or DSS-treated WT & Ccdc88Bmut mutant mice at indicated time points, & densitometric quantification of Ccdc88b immunoblot normalized to beta -actin±SEM (n = 3) (representative of one of two independent experiments); **P < 0.01 (two-tailed Student’s t-test). c Representative confocal microscopy images of tissue sections from colon of NT or DSS-treated mice at indicated times, & stained with antibodies against Ccdc88b (red), CD45 (green), & E-Cadherin (purple) & nuclei staining DAPI (blue). Scale bars, 100 μm. d Representative FACS plots & quantification of lamina propria cells stained for CD45 & for Ccdc88b antibodies for NT (n = 3) & DSS-treated WT mice (n = 4 for each time point) at indicated time points, data are representative of one experiment. e Representative confocal microscopy images of tissue sections from colon of NT or DSS-treated mice at day 8, & stained for Ccdc88b (red), CD3 (green) & CD11b (green); nuclei are stained with DAPI (blue). Scale bars, 100 μm. f same as in e for Ccdc88b (red), CD4 (green) & CD8 (green). Scale bars, 100 μm Image collected & cropped by CiteAb from the following publication (//www.nature.com/articles/s41467-017-01381-y), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-29475_rabbit-polyclonal-cd8-antibody-imgenex-abx-160a-20ug-310202416113534.jpg)
![Immunohistochemistry-Paraffin: S100B Antibody [NBP1-87102] - Analysis in human cerebral cortex and liver tissues. Corresponding S100B RNA-seq data are presented for the same tissues.](http://images.novusbio.com/fullsize/S100B-Antibody-Immunohistochemistry-Paraffin-NBP1-87102-img0020.jpg "<b>Orthogonal Strategies Validation. </b>Immunohistochemistry-Paraffin: S100B Antibody [NBP1-87102] - Analysis in human cerebral cortex and liver tissues. Corresponding S100B RNA-seq data are presented for the same tissues.")
![<b>Orthogonal Strategies Validation. </b>Western Blot: S100B Antibody [NBP1-87102] - Analysis in mouse cerebral cortex tissue.](http://images.novusbio.com/fullsize/S100B-Antibody-Western-Blot-NBP1-87102-img0010.jpg)
![Immunocytochemistry/Immunofluorescence: S100B Antibody [NBP1-87102] - Staining of human cell line U-2 OS shows localization to vesicles. Antibody staining Is shown in green.](http://images.novusbio.com/fullsize/S100B-Antibody-Immunocytochemistry-Immunofluorescence-NBP1-87102-img0018.jpg)
![Immunohistochemistry-Paraffin: S100B Antibody [NBP1-87102] - Staining of human skeletal muscle shows no positivity in myocytes as expected.](http://images.novusbio.com/fullsize/S100B-Antibody-Immunohistochemistry-Paraffin-NBP1-87102-img0025.jpg)
![Immunohistochemistry-Paraffin: S100B Antibody [NBP1-87102] - Staining of human cerebellum shows moderate to strong nuclear positivity in cells in purkinje cell layer.](http://images.novusbio.com/fullsize/S100B-Antibody-Immunohistochemistry-Paraffin-NBP1-87102-img0022.jpg)
![Immunohistochemistry-Paraffin: S100B Antibody [NBP1-87102] - Staining of human cerebral cortex shows moderate to strong nuclear positivity in glial cells.](http://images.novusbio.com/fullsize/S100B-Antibody-Immunohistochemistry-Paraffin-NBP1-87102-img0023.jpg)
![Immunohistochemistry-Paraffin: S100B Antibody [NBP1-87102] - Staining of human liver shows no positivity in hepatocytes as expected.](http://images.novusbio.com/fullsize/S100B-Antibody-Immunohistochemistry-Paraffin-NBP1-87102-img0024.jpg)
![Western Blot: GPER/GPR30 Antibody [NBP1-31239] - The MW of GPR30 is estimated to be 42 kDa, but higher MW sizes have been reported due to glycosylation and interaction with other proteins. Bands are identified as glycosylated and nonglycosylated based on reports cited in the text, but could include interaction with other proteins. For each GPER western, the membrane was stripped and reprobed for b-actin as a loading control. Quantitation of GPER was evaluated by summing all immunoreactive bands and dividing by b-actin, then normalizing to HBEC2-KT in each blot. Image collected and cropped by CiteAb from the following publication (biomedcentral.com/1471-2407/12/624), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/GPER-GPR30-Antibody-Western-Blot-NBP1-31239-img0012.jpg "Western Blot: GPER/GPR30 Antibody [NBP1-31239] - The MW of GPR30 is estimated to be 42 kDa, but higher MW sizes have been reported due to glycosylation and interaction with other proteins. Bands are identified as glycosylated and nonglycosylated based on reports cited in the text, but could include interaction with other proteins. For each GPER western, the membrane was stripped and reprobed for b-actin as a loading control. Quantitation of GPER was evaluated by summing all immunoreactive bands and dividing by b-actin, then normalizing to HBEC2-KT in each blot. Image collected and cropped by CiteAb from the following publication (biomedcentral.com/1471-2407/12/624), licensed under a CC-BY license.")
![Immunocytochemistry/Immunofluorescence: GPER/GPR30 Antibody [NBP1-31239] - Detection of GPER/GPR30 in HUVEC nucleus. Image courtesy of a product review by Dr. Subhadeep Chakrabarti of University of Alberta.](http://images.novusbio.com/fullsize/GPER-GPR30-Antibody-Immunocytochemistry-Immunofluorescence-NBP1-31239-img0010.jpg)
![<b>Genetic Strategies Validation. </b>Western Blot: GPER/GPR30 Antibody [NBP1-31239] - A. 50 ug 293T whole cell lysate/extract. B. 50 ug whole cell lysate/extract of GFP-human GPR30-transfected 293T cells (No boiling). C. 50 ug whole cell lysate/extract of GFP-human GPR30 and GPR30 siRNA-transfected 293T cells (No boiling). 5 % SDS-PAGE GPR30 antibody ) dilution: 1:1000](http://images.novusbio.com/fullsize/GPER-GPR30-Antibody-Western-Blot-NBP1-31239-img0011.jpg)
![Western Blot: GPER/GPR30 Antibody [NBP1-31239] - AhR & GPR30 receptors are present & functional in the MCF10AT1 cells. (A) RT-qPCR analysis of AhR & GPR30 mRNA expression levels represented in arbitrary units (a.u.) in the MCF10AT1 & MCF10CA1a.cl1 cells. MCF-7 cells were used as a control. Values represent mean ± SD of three independent experiments conducted in triplicate. (B) Representative Western blot analyses from three independent experiments of AhR & GPR30 protein expression in MCF10AT1 & MCF10CA1a.cl1 cells. MCF-7 cells were used as a control. (C) XRE-luciferase activity following 8 h exposure of MCF10AT1 cells to ITE at the indicated concentrations. TCDD 10−7 M was used as a control & results were expressed as % of TCDD 10−7 M activity. ***p < 0.001 in Student t-test. (D) XRE-luciferase activity upon 8 h of exposure to ITE 10−10 M alone or in combination with GNF351 at the indicated concentrations. TCDD 10−7 M was used as a control, & results were expressed as % of TCDD 10−7 M activity. Student t-tests revealed the statistically significant differences between unexposed & exposed cells: ***p < 0.001; & between ITE & ITE+GNF351: ###p < 0.001. Values in (C,D) represent mean ± SD of three independent experiments. (E) Representative Western blot analyses from three independent experiments of the phospho-MAPK/MAPK ratio upon exposure of MCF10AT1 cells to G1 (GPR30 agonist) for the times indicated, in the presence or absence of a 2 h pre-treatment with G15 (GPR30 antagonist). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32670863), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-31239_rabbit-polyclonal-gper-gpr30-antibody-310202416171440.jpg)
![Western Blot: GPER/GPR30 Antibody [NBP1-31239] - Effects of short-term exposure of BPA, B[a]P, ITE & G1 10−10 M on AIG & MFE are inhibited by siRNA-AhR & siRNA-GPR30. Representative Western blot analysis from three independent experiments of AhR & GPR30 expression in transfected MCF10AT1 cells with (A) siRNA-AhR, (B) siRNA-GPR30 or their scrambled controls. Quantification of protein expression levels was normalized against tubulin expression. (C,D) Secondary mammospheres formation & (E,F) average number of colonies in soft agar, with the following treatments: BPA and/or B[a]P, G1, or ITE, 10−10 M. Cells were transfected with either siRNA-AhR, siRNA-GPR30 or their scrambled controls before being subjected to the treatments. Treatments were maintained throughout the course of experiments. (mean ± SD of 2 independent experiments, in triplicate). ***p < 0.001, *p < 0.05 vs. their respective unexposed; ###p < 0.001 siRNA vs. scrambled in Student t-test. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32670863), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-31239_rabbit-polyclonal-gper-gpr30-antibody-310202416173515.jpg)
![Western Blot: GPER/GPR30 Antibody [NBP1-31239] - Human endothelial cells express GPR30 protein in the cell nucleus.(A) Confluent monolayers of HUVECs from 3 different cords were lysed & the protein lysates were immunoblotted for GPR30. alpha -tubulin was used as loading control. (B) HUVEC monolayers at 30–40% confluence were treated with 40 nM siRNA (control or GPR30_4) for 48 hours prior to lysis followed by immunoblotting of the cell lysates for GPR30. alpha -tubulin was used as loading control. Data shown are mean ± SEM of 4 independent experiments. ** & ## indicate p<0.01 compared to untreated & control siRNA-treated cells, respectively. (C) Confluent HUVECs grown on glass coverslips were fixed, permeabilized & immunostained with anti-GPR30 antibody. Nuclei were stained with Hoechst33342 dye. The merged image shows GPR30 (red) & nuclei (blue) in pseudocolor. Representative images from 3 independent experiments are shown. Bar, 20 µm. (D) Confluent HUVECs were lysed & fractionated into cytosolic (C) & nuclear (N) fractions prior to western blotting for eNOS, GPR30, p65, alpha -tubulin & c-Jun. A representative set of images (obtained from different membranes) from 3 independent experiments is shown. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/23285008), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-31239_rabbit-polyclonal-gper-gpr30-antibody-310202416175294.jpg)
![Western Blot: GPER/GPR30 Antibody [NBP1-31239] - Effects of short-term exposure of BPA, B[a]P, ITE & G1 10−10 M on AIG & MFE are inhibited by siRNA-AhR & siRNA-GPR30. Representative Western blot analysis from three independent experiments of AhR & GPR30 expression in transfected MCF10AT1 cells with (A) siRNA-AhR, (B) siRNA-GPR30 or their scrambled controls. Quantification of protein expression levels was normalized against tubulin expression. (C,D) Secondary mammospheres formation & (E,F) average number of colonies in soft agar, with the following treatments: BPA and/or B[a]P, G1, or ITE, 10−10 M. Cells were transfected with either siRNA-AhR, siRNA-GPR30 or their scrambled controls before being subjected to the treatments. Treatments were maintained throughout the course of experiments. (mean ± SD of 2 independent experiments, in triplicate). ***p < 0.001, *p < 0.05 vs. their respective unexposed; ###p < 0.001 siRNA vs. scrambled in Student t-test. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32670863), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-31239_rabbit-polyclonal-gper-gpr30-antibody-310202416173516.jpg)
![Western Blot: GPER/GPR30 Antibody [NBP1-31239] - Effects of short-term exposure of BPA, B[a]P, ITE & G1 10−10 M on AIG & MFE are inhibited by siRNA-AhR & siRNA-GPR30. Representative Western blot analysis from three independent experiments of AhR & GPR30 expression in transfected MCF10AT1 cells with (A) siRNA-AhR, (B) siRNA-GPR30 or their scrambled controls. Quantification of protein expression levels was normalized against tubulin expression. (C,D) Secondary mammospheres formation & (E,F) average number of colonies in soft agar, with the following treatments: BPA and/or B[a]P, G1, or ITE, 10−10 M. Cells were transfected with either siRNA-AhR, siRNA-GPR30 or their scrambled controls before being subjected to the treatments. Treatments were maintained throughout the course of experiments. (mean ± SD of 2 independent experiments, in triplicate). ***p < 0.001, *p < 0.05 vs. their respective unexposed; ###p < 0.001 siRNA vs. scrambled in Student t-test. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32670863), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-31239_rabbit-polyclonal-gper-gpr30-antibody-310202416163721.jpg)
![Western Blot: CIP2A Antibody [NB100-74663] - CIP2A downregulation reduces proliferation and induces apoptosis in melanoma cells. Immunoblot analysis showing reduction in cancerous inhibitor of protein phosphatase 2A protein levels 48 h post siRNA transfection and effects on proliferation and apoptosis markers. The figure is representative of at last three independent biological experiments. Image collected and cropped by CiteAb from the following publication (//doi.wiley.com/10.1002/cam4.425), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/CIP2A-Antibody-Western-Blot-NB100-74663-img0011.jpg "<b>Genetic Strategies Validation. </b>Western Blot: CIP2A Antibody [NB100-74663] - CIP2A downregulation reduces proliferation and induces apoptosis in melanoma cells. Immunoblot analysis showing reduction in cancerous inhibitor of protein phosphatase 2A protein levels 48 h post siRNA transfection and effects on proliferation and apoptosis markers. The figure is representative of at last three independent biological experiments. Image collected and cropped by CiteAb from the following publication (//doi.wiley.com/10.1002/cam4.425), licensed under a CC-BY license.")
![<b>Genetic Strategies Validation. </b>Immunohistochemistry: CIP2A Antibody [NB100-74663] - Characterization of CIP2A expression in a panel of normal human melanocytes (NHM) and melanoma cell lines. Cytoplasmic and nuclear expression of CIP2A in normal melanocytes, primary and metastatic melanoma cell lines assessed by immunohistochemical staining. CIP2A = cancerous inhibitor of protein phosphatase 2A. Image collected and cropped by CiteAb from the following publication (//doi.wiley.com/10.1002/cam4.425), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/CIP2A-Antibody-Immunohistochemistry-NB100-74663-img0012.jpg)
![Western Blot: CIP2A Antibody [NB100-74663] - Characterization of CIP2A expression in a panel of normal human melanocytes (NHM) and melanoma cell lines. Immunoblot analysis of protein expression levels of CIP2A. Image collected and cropped by CiteAb from the following publication (//doi.wiley.com/10.1002/cam4.425), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/CIP2A-Antibody-Western-Blot-NB100-74663-img0009.jpg)
![Western Blot: CIP2A Antibody [NB100-74663] - Characterization of CIP2A expression in a panel of normal human melanocytes (NHM) and melanoma cell lines. Cytoplasmic and nuclear expression of CIP2A in normal melanocytes, primary and metastatic melanoma cell lines assessed by immunoblot analysis. CIP2A = cancerous inhibitor of protein phosphatase 2A. Image collected and cropped by CiteAb from the following publication (//doi.wiley.com/10.1002/cam4.425), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/CIP2A-Antibody-Western-Blot-NB100-74663-img0010.jpg)
![Immunohistochemistry: CIP2A Antibody [NB100-74663] - Section of human colon carcinoma. Antibody: Affinity purified rabbit anti-CIP2A used at a dilution of 1:100. Detection: Red-fluorescent goat anti-rabbit IgG highly cross-adsorbed Antibody used at a dilution of 1:100.](http://images.novusbio.com/fullsize/CIP2A-Antibody-Immunohistochemistry-NB100-74663-img0008.jpg)
![Immunohistochemistry-Paraffin: CIP2A Antibody [NB100-74663] - Section of human colon carcinoma. Antibody: Affinity purified rabbit anti-CIP2A used at a dilution of 1:250. Detection: DAB](http://images.novusbio.com/fullsize/CIP2A-Antibody-Immunohistochemistry-Paraffin-NB100-74663-img0006.jpg)
![Immunohistochemistry-Paraffin: CIP2A Antibody [NB100-74663] - Section of human ovarian carcinoma. Antibody: Affinity purified rabbit anti-CIP2A used at a dilution of 1:250. Detection: DAB](http://images.novusbio.com/fullsize/CIP2A-Antibody-Immunohistochemistry-Paraffin-NB100-74663-img0007.jpg)
![Western Blot: CIP2A Antibody [NB100-74663] - CIP2A is an inhibitor of PP2A-mediated DAPK dephosphorylationRSC96 cells were transfected with control, CIP2A siRNA (A), DKK-CIP2A (B), or DAPK siRNA (C) for 48 h & then exposed to GAS6 (100 ng/ml) for 30 min. PP2A activity & immunoblotting evaluations of DKK, CIP2A, pDAPK, & DAPK were performed. (D) RSC96 cells were incubated with GAS6 (100 ng/ml) for 30 min & co-immunoprecipitation between CIP2A, pDAPK & PP2A was evaluated. Immunoprecipitated PP2A activity was measured. Data are the mean ± SD, & n = 3 for each time point. * p < 0.05, ** p < 0.01, vs. control. Image collected & cropped by CiteAb from the following publication (//www.oncotarget.com/lookup/doi/10.18632/oncotarget.23978), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-74663_rabbit-polyclonal-cip2a-antibody-310202415384132.jpg)
![Western Blot: CIP2A Antibody [NB100-74663] - CIP2A is an inhibitor of PP2A-mediated DAPK dephosphorylationRSC96 cells were transfected with control, CIP2A siRNA (A), DKK-CIP2A (B), or DAPK siRNA (C) for 48 h & then exposed to GAS6 (100 ng/ml) for 30 min. PP2A activity & immunoblotting evaluations of DKK, CIP2A, pDAPK, & DAPK were performed. (D) RSC96 cells were incubated with GAS6 (100 ng/ml) for 30 min & co-immunoprecipitation between CIP2A, pDAPK & PP2A was evaluated. Immunoprecipitated PP2A activity was measured. Data are the mean ± SD, & n = 3 for each time point. * p < 0.05, ** p < 0.01, vs. control. Image collected & cropped by CiteAb from the following publication (//www.oncotarget.com/lookup/doi/10.18632/oncotarget.23978), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-74663_rabbit-polyclonal-cip2a-antibody-310202415171316.jpg)
![Western Blot: CIP2A Antibody [NB100-74663] - GAS6 increases the amount of both CIP2A & p-DAPK in RSC96 cells(A) RSC96 cells were incubated with GAS6 (100 ng/ml), & immunoblotting evaluations of CIP2A & p-DAPK expression were performed. The lower panel shows the intensity during basal conditions from the scanned imaged (upper panel). (B) RSC96 cells incubated with & without GAS6 (100 ng/ml) for 30 min & analysed by immunofluorescence. (C) Immunohistochemistry images demonstrated that CIP2A expression levels were higher than sham levels at 14 days & 28 days in the cavernous nerve after BCNI. Image collected & cropped by CiteAb from the following publication (//www.oncotarget.com/lookup/doi/10.18632/oncotarget.23978), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-74663_rabbit-polyclonal-cip2a-antibody-310202415304268.jpg)
![Western Blot: CIP2A Antibody [NB100-74663] - CIP2A is an inhibitor of PP2A-mediated DAPK dephosphorylationRSC96 cells were transfected with control, CIP2A siRNA (A), DKK-CIP2A (B), or DAPK siRNA (C) for 48 h & then exposed to GAS6 (100 ng/ml) for 30 min. PP2A activity & immunoblotting evaluations of DKK, CIP2A, pDAPK, & DAPK were performed. (D) RSC96 cells were incubated with GAS6 (100 ng/ml) for 30 min & co-immunoprecipitation between CIP2A, pDAPK & PP2A was evaluated. Immunoprecipitated PP2A activity was measured. Data are the mean ± SD, & n = 3 for each time point. * p < 0.05, ** p < 0.01, vs. control. Image collected & cropped by CiteAb from the following publication (//www.oncotarget.com/lookup/doi/10.18632/oncotarget.23978), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-74663_rabbit-polyclonal-cip2a-antibody-310202415382441.jpg)
![Western Blot: CIP2A Antibody [NB100-74663] - GAS6 triggers p-Axl, p-DAPK & CIP2A to form a protein complex in RSC96 cells(A-B) Co-immunoprecipitation between p-Axl, p-DAPK & CIP2A with GAS6 stimulation for 30 min in RSC96 cells. Total lysate indicates 1/10 input in each experiment. The relative quantification of protein expression was normalized with respect to beta -actin expression. (C) Immunofluorescence image demonstrating co-localized CIP2A & p-Axl & co-localized p-Axl & p-DAPK (D) after GAS6 stimulation for 30 min in RSC96 cells. Image collected & cropped by CiteAb from the following publication (//www.oncotarget.com/lookup/doi/10.18632/oncotarget.23978), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-74663_rabbit-polyclonal-cip2a-antibody-31020241539737.jpg)
![Western Blot: CIP2A Antibody [NB100-74663] - CIP2A is an inhibitor of PP2A-mediated DAPK dephosphorylationRSC96 cells were transfected with control, CIP2A siRNA (A), DKK-CIP2A (B), or DAPK siRNA (C) for 48 h & then exposed to GAS6 (100 ng/ml) for 30 min. PP2A activity & immunoblotting evaluations of DKK, CIP2A, pDAPK, & DAPK were performed. (D) RSC96 cells were incubated with GAS6 (100 ng/ml) for 30 min & co-immunoprecipitation between CIP2A, pDAPK & PP2A was evaluated. Immunoprecipitated PP2A activity was measured. Data are the mean ± SD, & n = 3 for each time point. * p < 0.05, ** p < 0.01, vs. control. Image collected & cropped by CiteAb from the following publication (//www.oncotarget.com/lookup/doi/10.18632/oncotarget.23978), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-74663_rabbit-polyclonal-cip2a-antibody-310202415175242.jpg)
![Immunohistochemistry-Paraffin: CIP2A Antibody [NB100-74663] - GAS6 increases the amount of both CIP2A & p-DAPK in RSC96 cells(A) RSC96 cells were incubated with GAS6 (100 ng/ml), & immunoblotting evaluations of CIP2A & p-DAPK expression were performed. The lower panel shows the intensity during basal conditions from the scanned imaged (upper panel). (B) RSC96 cells incubated with & without GAS6 (100 ng/ml) for 30 min & analysed by immunofluorescence. (C) Immunohistochemistry images demonstrated that CIP2A expression levels were higher than sham levels at 14 days & 28 days in the cavernous nerve after BCNI. Image collected & cropped by CiteAb from the following publication (//www.oncotarget.com/lookup/doi/10.18632/oncotarget.23978), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-74663_rabbit-polyclonal-cip2a-antibody-310202415394520.jpg)
![Western Blot: CIP2A Antibody [NB100-74663] - CIP2A is an inhibitor of PP2A-mediated DAPK dephosphorylationRSC96 cells were transfected with control, CIP2A siRNA (A), DKK-CIP2A (B), or DAPK siRNA (C) for 48 h & then exposed to GAS6 (100 ng/ml) for 30 min. PP2A activity & immunoblotting evaluations of DKK, CIP2A, pDAPK, & DAPK were performed. (D) RSC96 cells were incubated with GAS6 (100 ng/ml) for 30 min & co-immunoprecipitation between CIP2A, pDAPK & PP2A was evaluated. Immunoprecipitated PP2A activity was measured. Data are the mean ± SD, & n = 3 for each time point. * p < 0.05, ** p < 0.01, vs. control. Image collected & cropped by CiteAb from the following publication (//www.oncotarget.com/lookup/doi/10.18632/oncotarget.23978), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-74663_rabbit-polyclonal-cip2a-antibody-310202415363717.jpg)
![Western Blot: CIP2A Antibody [NB100-74663] - Characterization of CIP2A expression in a panel of normal human melanocytes (NHM) & melanoma cell lines. (A) Immunoblot analysis & (B) quantification of protein expression levels of CIP2A (C) CIP2A mRNA expression measured by qRT-PCR. NHM1 line was used as calibrator. (D) Cytoplasmic & nuclear expression of CIP2A in normal melanocytes, primary & metastatic melanoma cell lines assessed by immunoblot analysis & (E) by immunohistochemical staining. CIP2A, cancerous inhibitor of protein phosphatase 2A. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25663244), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-74663_rabbit-polyclonal-cip2a-antibody-31020241539738.jpg)
![Western Blot: CIP2A Antibody [NB100-74663] - GAS6 triggered Schwann cell proliferation primarily through CIP2A & DAPK(A) RSC96 cells were transfected with either control or DAPK siRNA for 48 h & then exposed to GAS6 (100 ng/ml) for 30 min. Immunoblotting evaluations of pAxl, Axl, CIP2A, DAPK, pERK1/2, ERK1/2, pAKT, AKT, Myc & Survivin. (B) RSC96 cells were transfected with either control or CIP2A siRNA for 48 h & then exposed to GAS6 (100 ng/ml) for 30 min. Immunoblotting evaluations of pAxl, Axl, DAPK, pDAPK, pERK1/2, ERK1/2, pAKT, AKT, Myc & Survivin. (C) DAPK or CIP2A was knocked down for 48 h then RSC96 cells were incubated with GAS6 (100 ng/ml) at the indicated hours. Cell viability was analysed via the WST-1 assay. Data are the mean ± SD, & n = 3 for each time point. * p < 0.05, ** p < 0.01 vs. scramble. Image collected & cropped by CiteAb from the following publication (//www.oncotarget.com/lookup/doi/10.18632/oncotarget.23978), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-74663_rabbit-polyclonal-cip2a-antibody-310202415532020.jpg)
![Western Blot: BRCA1 Antibody (RAY) [NB100-598] - Analysis of BRCA1 on MCF7 lysate.](http://images.novusbio.com/fullsize/BRCA1-Antibody-RAY-Western-Blot-NB100-598-img0006.jpg "Western Blot: BRCA1 Antibody (RAY) [NB100-598] - Analysis of BRCA1 on MCF7 lysate.")
![Immunocytochemistry/Immunofluorescence: BRCA1 Antibody (RAY) [NB100-598] - BRCA (RAY) antibody was tested in MCF-7 cells with FITC (green). Nuclei and alpha-tubulin were counterstained with DAPI (blue) and DyLight 550 (red).](http://images.novusbio.com/fullsize/BRCA1-Antibody-RAY-Immunocytochemistry-Immunofluorescence-NB100-598-img0005.jpg)
![Flow Cytometry: BRCA1 Antibody (RAY) [NB100-598] - Intracellular flow cytometric staining of 1 x 10^6 MCF-7 cells using BRCA1 antibody (dark blue) and isotype control (orange). An antibody concentration of 1 ug/1x10^6 cells was used.](http://images.novusbio.com/fullsize/BRCA1-Antibody-RAY-Flow-Cytometry-NB100-598-img0008.jpg)
![Western Blot: Cited-2 Antibody (JA22) [NB100-136] - Total protein from human HeLa and MCF7 and mouse 3T3 cell lines was separated on a 12% gel by SDS-PAGE, transferred to PVDF membrane and blocked in 5% non-fat milk in TBST. The membrane was probed with 2.0 ug/ml anti-Cited in 1% non-fat milk in TBST and detected with an anti-mouse HRP secondary antibody using West Pico PLUS chemiluminescence detection reagent.](http://images.novusbio.com/fullsize/Cited-2-Antibody-JA22-Western-Blot-NB100-136-img0005.jpg "Western Blot: Cited-2 Antibody (JA22) [NB100-136] - Total protein from human HeLa and MCF7 and mouse 3T3 cell lines was separated on a 12% gel by SDS-PAGE, transferred to PVDF membrane and blocked in 5% non-fat milk in TBST. The membrane was probed with 2.0 ug/ml anti-Cited in 1% non-fat milk in TBST and detected with an anti-mouse HRP secondary antibody using West Pico PLUS chemiluminescence detection reagent.")
![Immunocytochemistry/Immunofluorescence: Cited-2 Antibody (JA22) [NB100-136] - The Cited-2 (JA22) antibody was tested at a 1:250 dilution in HeLa cells against Dylight 488 (Green). Beta-tubulin and nuclei were counterstained against Dylight 550 (Red) and DAPI (Blue).](http://images.novusbio.com/fullsize/Cited-2-Antibody-JA22-Immunocytochemistry-Immunofluorescence-NB100-136-img0003.jpg)
![Immunohistochemistry-Paraffin: Cited-2 Antibody (JA22) [NB100-136] - IHC analysis of a formain fixed paraffin embedded (FFPE) tissue section of human breast cancer using Cited-2 antibody at 1:500 dilution. The primary antibody bound to CAIX antigens in the tissue section was detected using a HRP labeled secondary antibody and DAB reagent. Nuclei of the cells were counterstained with hematoxylin. Staining was localized to the nucleus.](http://images.novusbio.com/fullsize/Cited-2-Antibody-JA22-Immunohistochemistry-Paraffin-NB100-136-img0004.jpg)
![Immunocytochemistry/Immunofluorescence: BMI-1 Antibody (LLBmi1-1) [NBP1-96140] - HeLa cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.5% Triton X-100 in PBS for 5 minutes. The cells were incubated with anti- NBP1-96140 at 2 ug/ml overnight at 4C and detected with an anti-mouse Dylight 488 (Green) at a 1:1000 dilution for 60 minutes. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 100X objective and digitally deconvolved.](http://images.novusbio.com/fullsize/BMI-1-Antibody-LLBmi1-1-Immunocytochemistry-Immunofluorescence-NBP1-96140-img0008.jpg "Immunocytochemistry/Immunofluorescence: BMI-1 Antibody (LLBmi1-1) [NBP1-96140] - HeLa cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.5% Triton X-100 in PBS for 5 minutes. The cells were incubated with anti- NBP1-96140 at 2 ug/ml overnight at 4C and detected with an anti-mouse Dylight 488 (Green) at a 1:1000 dilution for 60 minutes. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 100X objective and digitally deconvolved.")
![Immunocytochemistry/Immunofluorescence: BMI-1 Antibody (LLBmi1-1) [NBP1-96140] - NIH3T3 cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.5% Triton X-100 in PBS for 5 minutes. The cells were incubated with anti- NBP1-96140 at 2 ug/ml overnight at 4C and detected with an anti-mouse Dylight 488 (Green) at a 1:1000 dilution for 60 minutes. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 100X objective and digitally deconvolved.](http://images.novusbio.com/fullsize/BMI-1-Antibody-LLBmi1-1-Immunocytochemistry-Immunofluorescence-NBP1-96140-img0009.jpg)
![Western Blot: BMI-1 Antibody (LLBmi1-1) [NBP1-96140] - Western blot analysis of Bmi1 expression in 1) U2OS and 2) K562 whole cell lysates using NBP1-96140.](http://images.novusbio.com/fullsize/BMI-1-Antibody-LLBmi1-1-Western-Blot-NBP1-96140-img0002.jpg)
![Immunocytochemistry/Immunofluorescence: BMI-1 Antibody (LLBmi1-1) [NBP1-96140] - Bmi1 antibody was tested in U2OS cells with FITC (green). Nuclei and alpha-tubulin were counterstained with Dapi (blue) and Dylight 550 (red).](http://images.novusbio.com/fullsize/BMI-1-Antibody-LLBmi1-1-Immunocytochemistry-Immunofluorescence-NBP1-96140-img0003.jpg)
![Flow Cytometry: BMI-1 Antibody (LLBmi1-1) [NBP1-96140] - An intracellular stain was performed on NIH3T3 cells with BMI-1 Antibody (LLBmi1-1) NBP1-96140 (blue) and a matched mouse IgG2b Kappa isotype control (orange) MAB004. Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature, followed by Mouse IgG (H+L) Cross-Adsorbed Secondary Antibody, Dylight 550 (35503, Thermo Fisher).](http://images.novusbio.com/fullsize/BMI-1-Antibody-LLBmi1-1-Flow-Cytometry-NBP1-96140-img0012.jpg)
![Western Blot: BMI-1 Antibody (LLBmi1-1) [NBP1-96140] - BMI-1 expression in human cell lines (MCF-7, K562 and A459). Image from verified customer review.](http://images.novusbio.com/fullsize/BMI-1-Antibody-LLBmi1-1-Western-Blot-NBP1-96140-img0004.jpg)
![Flow Cytometry: BMI-1 Antibody (LLBmi1-1) [NBP1-96140] - An intracellular stain was performed on U2OS cells with BMI-1 Antibody [LLBmi1-1] NBP1-96140AF488 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 488.](http://images.novusbio.com/fullsize/BMI-1-Antibody-LLBmi1-1-Flow-Cytometry-NBP1-96140-img0005.jpg)
![Flow Cytometry: BMI-1 Antibody (LLBmi1-1) [NBP1-96140] - An intracellular stain was performed on U2OS cells with BMI-1 [LLBmi1-1] Antibody NBP1-96140 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 1.0 ug/mL for 30 minutes at room temperature, followed by Mouse IgG (H+L) Cross-Adsorbed Secondary Antibody, Dylight 550 (84540, Thermo Fisher).](http://images.novusbio.com/fullsize/BMI-1-Antibody-LLBmi1-1-Flow-Cytometry-NBP1-96140-img0007.jpg)
![Flow Cytometry: BMI-1 Antibody (LLBmi1-1) [NBP1-96140] - An intracellular stain was performed on U937 cells with BMI-1 Antibody (LLBmi1-1) NBP1-96140 (blue) and a matched mouse IgG2b Kappa isotype control (orange) MAB004. Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature, followed by Mouse IgG (H+L) Cross-Adsorbed Secondary Antibody, Dylight 550 (35503, Thermo Fisher).](http://images.novusbio.com/fullsize/BMI-1-Antibody-LLBmi1-1-Flow-Cytometry-NBP1-96140-img0011.jpg)
![Western Blot: BubR1 Antibody (8G1) [NB100-353] - BUBR1 detected in HeLa cell lysate using NB 100-353.](http://images.novusbio.com/fullsize/BubR1-Antibody-8G1-Western-Blot-NB100-353-img0006.jpg "Western Blot: BubR1 Antibody (8G1) [NB100-353] - BUBR1 detected in HeLa cell lysate using NB 100-353.")
![Immunocytochemistry/Immunofluorescence: BubR1 Antibody (8G1) [NB100-353] - Immunofluorescence of an asynchronous cycling population of human cells (U2OS) with NB100-353. No signal is detected from interphase cells, whereas cells undergoing mitosis accumulate BubR1 at the kinetochores. Image reveals kinetochores at prometaphase. Image courtesy of Luke Hughes-Davies and Rhiannon Jade, Gurdon Institute, Cambridge, UK.](http://images.novusbio.com/fullsize/BubR1-Antibody-8G1-Immunocytochemistry-Immunofluorescence-NB100-353-img0005.jpg)
![Flow Cytometry: BubR1 Antibody (8G1) [NB100-353] - An intracellular stain was performed on HeLa cells with BubR1 Antibody (8G1)NB100-353C (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Dylight 650.](http://images.novusbio.com/fullsize/BubR1-Antibody-8G1-Flow-Cytometry-NB100-353-img0008.jpg)
![Flow Cytometry: BubR1 Antibody (8G1) [NB100-353] - Intracellular flow cytometric staining of 1 x 10^6 HEK-293 cells using BubR1 antibody (dark blue). Isotype control shown in orange. An antibody concentration of 1 ug/1x10^6 cells was used.](http://images.novusbio.com/fullsize/BubR1-Antibody-8G1-Flow-Cytometry-NB100-353-img0007.jpg)